tbuckley/cabot-search huggingface dataset:
X-RAY SEMINAR OF THE MONTH
Authors: J. H. T.
Journal: JAMA (1961)

In this issue ofThe Journal, p. 202, the first X-Ray Seminar is presented. Subsequent seminars will appear at regular intervals. The program is planned so that basic concepts of radiology will be explored and the diagnostic interpretations substantiated. The establishment of such a section inThe Journalwas suggested by Dr. Laurence L. Robbins, Chief of the Department of Radiology at the Massachusetts General Hospital, successor to George W. Holmes and Aubrey O. Hampton. This is the second in the series of a planned program of postgraduate education, which hopefully will contribute to undergraduate education as well. The Fracture of the Month was the initial venture. The third exercise, scheduled for later this year, will embrace selected items in dermatology. Other exercises are being explored. The institution of an x-ray seminar from the M.G.H. provides the opportunity to recount the early development of the Department of Roentgenology in one
Neonatal detection of generalized resistance to thyroid hormone
Authors: R. E. Weiss
Journal: JAMA (1990)

Generalized resistance to thyroid hormone (GRTH) is an inherited disease that is usually suspected when elevated serum thyroid hormone levels are associated with nonsuppressed thyrotropin. Often these test results are obtained because of short stature, decreased intelligence, and/or hyperactivity with learning disability noted in childhood and adolescence, or because of goiter in adulthood. We detected GRTH at birth by analysis of blood obtained during routine neonatal screening. The proposita, born to a mother with GRTH, had a thyrotropin level of 26 mU/L and a corresponding thyroxine concentration of 656 nmol/L (normal, 84 to 232 nmol/L). Administration of thyroid hormone in doses eightfold to 10-fold above replacement levels (liothyronine sodium, 21 μ/kg per day, and levothyroxine sodium, 44 μg/kg per day) were required to reduce serum thyrotropin to normal levels without induction of hypermetabolism. This case, and the retrospective finding of high thyroxine levels in five newborns subsequently diagnosed as having GRTH, suggest that measurement of thyroxine at birth, in conjunction with thyrotropin, could allow the early detection of GRTH. (<i>JAMA</i>. 1990;264:2245-2250)
Software
Authors: Thomas R. Kosten
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Health Resources and Services Administration
Authors: D. N. Sundwall
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chorea
Authors: Ronald H. Lands
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Natural interferon alfa for treatment of condylomata acuminata
Authors: A. E. Friedman-Kien
Journal: JAMA (1988)

The activity of natural (leukocyte) interferon alfa in the treatment of condylomata acuminata was assessed in a randomized, double-blind, placebo-controlled, multicenter trial. Interferon alfa (Alferon N Injection) or placebo was injected into lesions twice weekly for up to eight weeks. Eighty-six patients were given interferon alfa, and 72 were given placebo. Eighty-six percent of interferon alfa—treated patients and 89% of placebo-treated patients had received previous therapy for condylomata acuminata. Side effects, usually flulike symptoms, occurred briefly after the injections; if present, they disappeared before the end of the third week of therapy. Treatment completely eliminated warts in 62% of interferon alfa—treated patients compared with only 21% of placebo-treated patients. Natural interferon alfa given intralesionally is an effective and safe treatment even in patients with recurrent or recalcitrant genital warts. (<i>JAMA</i>1988;259:533-538)
MYOPLASTY TO RESTORE FUNCTION IN EXTENSOR COMMUNIS DIGITORUM
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: Arthur W. Allen
Journal: New England Journal of Medicine (1949)

Presidential AddressYour vote of confidence in me is deeply appreciated. No member of the Massachusetts Medical Society receiving this great honor could possibly fail to be duly impressed. I know that there are many among you more deserving of this recognition than I. Having observed the work of the Society closely for many years and pursuing a careful study of its activities during the past twelve months, I realize the tremendous responsibility you have placed upon me. It is with full awareness of my own inadequacies that I accept this position as your moderator. I assure you that I . . .
True
Authors: H Hasle, G Kardos, G Kerndrup, CM Niemeyer, H Ptoszkova, R Slater, J Starý, B Stollmann-Gibbels, ER van Wering, M Aricò, G Basso, A Biondi ,  A Cantù Rajnoldi, U Creutzig,  J Ritter ,  M Zimmermann, S Fenu ,  AM Testi, C Fonatsch,  G Mann, OA Haas , J Harbott
Journal: Leukemia (1999)
Classic Case
Authors: Robert J. Havey
Journal: JAMA (1984)

"N. W. is a 42-year-old white male who received the diagnosis of squamous cell carcinoma of the lung two years prior to this hospital admission after presenting to his physician's office with complaints of blood-tinged sputum and shortness of breath. His physical exam revealed...." The speaker rambled on in the cold matter-of-fact banter of modern medicine as the diseased products of Mr W.'s autopsy were projected on the screen. "This slide illustrates quite nicely a metastatic nodule in the right cerebral hemisphere...." My mind drifted back to the night N. W. was brought to the hospital. It was a cold, dark midnight with the autumn drizzle enhancing the eeriness of the fluorescent corridor. The tone of my pager sounded his arrival; the nurse warned me that he didn't look good. The room was dimly lit when I arrived; his wife and two sons were silently gathered at the foot of
ORDEAL OF THE BIER.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections
Journal: Annals of the Rheumatic Diseases (2012)

In the first paragraph of the Results section entitled "Number of joint injections and doses of betamethasone" the first reference to figure 1C should actually be to figure 1B, and the first reference to figure 1B should actually be to figure 1C.Therefore, the sentence should read: "A total of 1373 injections were first-time injections, 531 were second-time injections in a previously injected joint and 262 were third time injections (figure 1B).At the baseline visit, 522 injections were given (see figure 1C for details)."Again in the Results section, under the heading "Long-term efficacy of joint injections" the first reference to figure 1B should actually be to figure 1C ( paragraph 2), and the first reference to figure 1C should actually be to figure 1B ( paragraph 3).We apologise for these errors.
Urinary Markers for Measuring Exposure to Endogenous and Exogenous Alkylating Agents and Precursors
Authors: David E. G. Shuker, Virginie Prevost, Marlin D. Friesen, Dongxin Lin, Hiroshi Ohshima, Helmut Bartsch
Journal: Environmental Health Perspectives (1993)

Noninvasive methodologies for measuring carcinogen exposure in humans, based on the use of urinary markers, are being developed and validated for use in molecular epidemiological studies. A range of 3-alkyladenines can be determined in urine samples by an immunoaffinity purification-GC/MS approach [3-methyladenine, 3-ethyladenine, 3-(2-hydroxyethyl)adenine, and 3-benzyladenine]. Using this method, recent results in human subjects suggest that urinary 3-alkyladenines are potentially useful markers of alkylating agent exposure, particularly where the backgrounds of such adducts are much lower than 3-methyladenine. Urinary excretion of S-benzylmercapturic acid has been studied in experimental animals as a marker of exposure to benzylating agents such as N-nitroso-methylbenzylamine. 3-Nitrotyrosine (NTyr) is formed in vivo in tissue or blood proteins after exposure to nitrosating and/or nitrating agents such as tetranitromethane. After turnover of proteins, NTyr is released and excreted in urine as metabolites 3-nitro-4-hydroxy-phenylacetic acid and 3-nitro-4-hydroxyphenylacetic acid, which are determined by GC with a thermal energy analyzer. The sensitivity and specificity, combined with ease of use, of these noninvasive biomonitoring approaches means that they may be readily incorporated into molecular epidemiological studies in which exposure to nitrosating and alkylating agents may be important risk factors.
Hepatic stellate cell activation in genetic hemochromatosis: Lobular distribution, effect of increasing hepatic iron and response to phlebotomy Liver Unit, Queensland Institute of Medical Research and 1Department of Pathology, Royal Brisbane Hospital, Brisbane, QLD., AUSTRALIA, 4029
Journal: Hepatology (1995)

Iron overload is a key contributor to the pathogenesis of multiple disorders including the sideroblastic anemias. The specific iron compounds present in tissues or cells that are the target of iron deposition remain poorly understood, but there is evidence that some forms are magnetically active. We have developed a simple and specific method to purify iron-overloaded red blood cells using magnetic affinity columns. Here we describe this method and characterize purified Sod2-deficient siderocytes.RBC derived from mice transplanted with Sod2-deficient hematopoietic stem cells served as a source of iron-laden cells. Purification was based upon the observation that iron deposits in Sod2-deficient cells are “magnetically susceptible” and allow for retention of iron-laden cells in a strong magnetic field. Peripheral blood from Sod2-deficient chimeric mice was passed through magnetic separation columns; iron-overloaded cells were eluted and characterized by flow cytometry, Western blot, and microscopy.We were able to purify 2.8% of the total red cells as iron-laden siderocytes. The magnetically purified Sod2-deficient cells were predominantly identified as reticulocytes. They had numerous siderotic granules, produced enhanced levels of reactive oxygen species, and showed increased protein oxidative damage, mitochondrial enrichment, and mitochondrial hyperpolarization.Our method can be used to purify iron-laden cells as well as iron-associated subcellular fractions prepared from iron-loaded tissues, allowing elucidation of the structure, location, and protein composition of such iron deposits. This data will help develop our understanding of the pathogenesis of SA and other disorders characterized by iron overload.
FRI0055 Histone deacetylase 1 (HDAC1): a novel therapeutic target in rheumatoid arthritis
Authors: L Göschl, M Bonelli, V Saferding, T Preglej, C Seiser, S Knapp, J Backlund, C Bock, P Mathias, K Hirahara, C Scheinecker, G Steiner, W Ellmeier
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Autoreactive T cells have been shown to play a major role in Rheumatoid Arthritis, which drive the inflammatory process leading to an irreversible destruction of the joints. Gene transcription and regulation of proinflammatory cytokine production in T cells is regulated by epigenetic mechanisms. Histone deacetylases (HDACs) modify the epigenetic landscape by removing acetyl groups of lysine residues of histones, resulting in chromatin condensation and repression of transcription. The application of pan-HDAC inhibitors has been shown to be a potential therapeutic strategy. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. <h3>Objectives</h3> Our aim was to to investigate whether HDAC1 is linked with the development of autoimmune diseases. Therefore we were using the collagen-induced arthritis model (CIA) and the experimental autoimmune encephalomyelitis model (EAE). <h3>Methods</h3> Mice with a T cell specific deletion of HDAC1 (HDAC1cKO) were generated by using the CD4Cre/LoxP system. The clinical and the histological phenotype were assessed in the CIA and the EAE. Anti-collagen antibody levels were determined by ELISA. Qualitative and quantitative analysis of T cell subsets of the spleen and draining LN were assessed using flow cytometry. Additionally comparative RNA-sequencing of CD4<sup>+</sup> T cells from wild type (WT) and HDAC1cKO mice was performed. <h3>Results</h3> To address whether HDAC1 is involved in the pathogenesis of autoimmune diseases we induced the CIA and the EAE in WT and HDAC1cKO mice. Unexpectedly, HDAC1cKO mice did not develop any clinical or histological signs of inflammation, despite the presence of serum anti-CII antibodies. A similar protection against disease development was also observed in the context of EAE. A molecular analysis of HDAC1cKO CD4<sup>+</sup> T cells revealed increased STAT1 phosphorylation in activated HDAC1cKO CD4<sup>+</sup> T cells in comparison to WT cells. This was accompanied with an impaired expression of CCR6 in activated HDAC1cKO CD4<sup>+</sup> T cells, which is an essential chemokine receptor for the development of arthritis and EAE. In line with this finding we observed increased expression of CCR6 in STAT1<sup>-/-</sup> CD4<sup>+</sup> T cells. This indicates a negative role of STAT1 in the regulation of CCR6 expression. <h3>Conclusions</h3> Our data show the importance of HDAC1 as a key immune regulator in the pathogenesis of collagen induced arthritis. Therefore it might be considered as an interesting novel therapeutic target in RA. <h3>Disclosure of Interest</h3> None declared
Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.
Authors: Haider Samawi, Yaling Yin, Howard John Lim, Daniel John Renouf, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2017)

e18163 Background: No standard surveillance strategy exists following resection of pancreas cancer. Our aims were to describe patterns of surveillance and to evaluate their impact on outcomes. Methods: Patients who received at least one cycle of adjuvant gemcitabine or 5-fluorouracil monotherapy at any 1 of 5 cancer centers in British Columbia from 2004 to 2015 were included. Surveillance was divided into two groups: discharged to primary care physicians (PCP) or follow up with oncologists (ONC) that included regular clinical assessments, laboratory testing and/or imaging. Results: We identified 147 patients. Median age at diagnosis was 64 (range 38-85) years and 48% were men. More patients were followed by ONC than PCP (66% vs. 44%). ONC were more likely to follow patients with T3/4 (78% vs. 62%, P = 0.03), while all other prognostic factors were balanced between the two groups. At the time of analysis, 68% of patients had a documented recurrence and 59% died. The median overall survival (OS) was 2.82 (95% CI 2.17-3.32) years in the ONC group and 3.35 (95% CI 2.85-5.06) years in the PCP group while the median relapse free survival (RFS) was 1.4 (95% CI 1.37-1.77) and 2.4 (95% CI 2.07-4.59) years, respectively. On multivariate analysis, there was no significant difference in OS between ONC and PCP-driven surveillance (HR 1.23; 95% CI 0.74-2.04, P = 0.4); however, RFS favored the PCP group (HR 1.62; 95% CI 1.01-2.56, P = 0.04, for oncology). On recurrence, 51% of patients received chemotherapy where the most common first line regimens were FOLFIRINOX (21%) and Gemcitabine/Nab-paclitaxel (20%). Patients followed by ONC were more likely to receive chemotherapy on recurrence than those followed by PCP (58% vs. 34%, respectively, P = 0.03), however, there was no difference in survival after recurrence between PCP &amp; ONC (recurrence to death, 5.7 vs 8.9 months, respectively (P = 0.21). Conclusions: Surveillance tests and imaging performed by ONC detected recurrences earlier and correlated with a higher likelihood of aggressive therapy when compared to follow up by PCPs, but this did not result in OS differences. PCPs may have a larger role in the follow up care of selected patients with resected pancreas cancer.
Anton Chekhov
Authors: R. A. Norton
Journal: New England Journal of Medicine (1953)

ONCE, in his later years, Anton Chekhov was walking with a friend after a rainstorm. "Someone ought to write a vaudeville sketch," he said. "Two people wait in an empty barn for the rain to pass. They joke, they laugh, they dry their umbrellas, make love to each other. Then the rain stops, there is sunshine, and suddenly he dies from heart failure.""Good heavens!" exclaimed his companion. "What kind of vaudeville would that be?""Well," he answered, "such is life, is it not? We joke and laugh and then — bang! All is over."1 Chekhov's own life was like . . .
Evaluation multicentrique et prospective du dispositif GATEKEEPER® dans le traitement du reflux gastro-oesophagien symptomatique: résultats à 2 ans
Authors: J Boyer, V Quentin, J Baudon, T Ponchon, F Mion, T Barrioz, B Vedrenne, P Bauret, P Houcke, P Bulois, G Cadiot, H Claudez
Journal: Endoscopy (2008)

Objectif: Evaluer à 2 ans l'efficacité et la tolérance d'un dispositif de traitement endoscopique du reflux gastro-oesophagien (RGO) par implantation de matériel prothétique bio-inerte: le Gatekeeper®.